Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines Differential accumulation and metabolism

Biochemical Pharmacology

Volumn 57, Issue 11, 1999, Pages 1283-1295

  Rivera, Maria I ^a   Stinson, Sherman F ^a   Vistica, David T ^a   Jorden, Jean L ^b   Kenney, Susan ^a   Sausville, Edward A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

Antineoplastic agent; Drug metabolism; Renal carcinoma; Thiophene

Indexed keywords

2,5 BIS(5 HYDROXYMETHYL 2 THIENYL)FURAN; ANTINEOPLASTIC AGENT; CYTOCHROME P450; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG METABOLISM; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PRIORITY JOURNAL;

CARBON RADIOISOTOPES; CARCINOMA, RENAL CELL; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; FURANS; HUMANS; KIDNEY NEOPLASMS; RADIOPHARMACEUTICALS; THIOPHENES; TUMOR CELLS, CULTURED;

EID: 0033152250     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00046-5     Document Type: Article

References (31)

1. Boyd M.R. The future of drug development. Niederhuber J.E., Current Therapy in Oncology. 1993;11-22 BC Decker, Inc, Philadelphia.
2. Boyd M.R., Paull K. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev Res. 34:1995;91-109.
3. Paull K.D., Shoemaker R.H., Hodes L., Monks A., Scudiero D.A., Rubinstein L., Plowman J., Boyd M.R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines Development of mean graph and COMPARE algorithm . J Natl Cancer Inst. 81:1989;1088-1092.
4. Boyd M.R., Paull K.D., Rubinstein L.R. Data display and analysis strategies for the NCI disease oriented in vitro antitumor drug screen. Valeriote F.A., Korbit T., Baker L., Cytotoxic Anticancer Drugs Models and Concepts for Drug Discovery and Development . 1992;11-34 Academic Publishers, Boston.
5. Weinstein J.N., Myers T.G., O'Connor P.M., Friend S.H., Fornace A.J. Jr, Kohn K.W., Fojo T., Bates S.E., Rubinstein L.V., Anderson N.L., Buolamwini J.K., van Osdol W.W., Monks A.P., Scudiero D.A., Sausville E.A., Zaharevitzm D.W., Bunow B., Viswanadhan V.N., Johnson G.S., Wittes R.E., Paull K.D. An information-intensive approach to the molecular pharmacology of cancer. Science. 275:1997;343-349.
6. Alvarez M., Paull K., Monks A., Hose C., Lee J.-S., Weinstein J., Grever M.R., Bates S., Fojo T. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein expression in the cell lines of the National Cancer Institute Anticancer Drug Screen. J Clin Invest. 95:1995;2205-2214.
7. Bishop P.C., Wosikowski K., Myres T.G., Weinstein J.N., Sausville E., Paull K.D., Bates S.E. Identification of compounds targeting the epidermal growth factor receptor signaling pathway using the NCI drug screen database. Proc Am Assoc Cancer Res. 39:1998;303.
8. Wosikowski K., Schuurhuis D., Johnson K., Paull K.D., Myers T.G., Weinstein J.N., Bates S.E. Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. J Natl Cancer Inst. 89:1997;1505-1515.
9. Kagan J. Naturally ocurring di- and trithiophenes. Prog Chem Nat Prod. 56:1991;87-169.
10. Hudson J.B., Graham E.A., Miki N., Towers G.H.N., Hudson L.L., Rossi R., Carpita A., Neri D. Photoactive antiviral and cytotoxic activity of synthetic thiophenes and their acetylenic derivatives. Chemosphere. 19:1989;1329-1343.
11. Hudson J.B., Harris L., Marles R.J., Arnason J.T. The anti-HIV activities of photoactive terthiophenes. Photochem Photobiol. 58:1993;246-250.
12. Frohlich E.D. Ticrynafen A new thiazid-like but uricosuric antihypertensive diuretic . N Engl J Med. 301:1979;1378-1382.
13. Lemieux G., Kiss A., Vinay P., Gougoux A. Nature of the uricosuric effect of tienilic acid, a new diuretic. Kidney Int. 12:1977;104-114.
14. Jackman A.L., Farrugia D.C., Gibson W., Kimbell R., Harrap K.R., Stephens T.C., Azab M., Boyle F.T. ZD1694 (Tomudex) A new thymidylate synthase inhibitor with activity in colorectal cancer . Eur J Cancer. 31:1995;1277-1282.
15. Rustum Y.M., Harstrick A., Cao S., Vanhoefer U., Yin M.-B., Wilke H., Seeber S. Thymidylate synthase inhibitors in cancer therapy Direct and indirect inhibitors . J Clin Oncol. 15:1997;389-400.
16. Abelson M.B., Sloan J. Nonsteroidal anti-inflammatory drugs. Current ophthalmic therapy. J Fla Med Assoc. 81:1994;261-263.
17. Gentiletti A.A. Tenoxicam, a new non-steroidal anti-inflammatory drug in the prolonged treatment of rheumatoid arthritis. Eur J Rheumatol Inflamm. 9:1987;91-94.
18. Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbot B.J., Mayo J.G., Shoemaker R.H., Boyd M.R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48:1988;589-601.
19. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J., Boyd M.R. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst. 83:1991;757-766.
20. Stinson S.F., Alley M.C., Kopp W.C., Fiebig H.-H., Mullendore L.A., Pittman A.F., Kenney S., Keller J., Boyd M.R. Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer-drug screen. Anticancer Res. 12:1992;1035-1054.
21. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. New colorimetric cytotoxicity assay for anticancer drug screening. J Natl Cancer Inst. 82:1990;1107-1112.
22. Scudiero D.A., Shoemaker R.H., Paull K.D., Monks A., Tierney S., Nofziger T.H., Currens M.J., Seniff D., Boyd M.R. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 48:1988;4827-4833.
23. Plowman J., Dykes D.J., Hollingshead M., Simpson-Herren L., Alley M.C. Human tumor xenograft models in NCI drug development. Teicher B., Anticancer Drug Development Guide Preclinical Screening, Clinical Trials and Approval . 1997;101-125 Humana Press, Totowa.
24. Graham J. Isolation of subcellular organelles and membranes. Rickwood D., Centrifugation, a Practical Approach. 1984;161-182 IRL Press, Oxford.
25. Carter C.A., Waund W.R., Plowman J., Alley M.C. In vivo spectrum of antitumor activity of a thiophene derivative, NSC 652287D. Proc Am Assoc Cancer Res. 37:1996;393.
26. Albert A. Selective Toxicity The Physico-Chemical Basis of Therapy . 1985;Chapman & Hall, New York.
27. Mansuy D., Valadon P., Erdelmeier I., Lopez-Garcia P., Amar C., Girault J.-P., Dansette P.M. Thiophene S-oxides as new reactive metabolites Formation by cytochrome P450 dependent oxidation and reaction with nucleophiles . J Am Chem Soc. 113:1991;7825-7826.
28. Dansette P.M., Thang D.C., Elamri H., Mansuy D. Evidence for thiophene-S-oxide as a primary reactive metabolite of thiophene in vivo Formation of a dihydrothiophene sulfoxide mercapturic acid . Biochem Biophys Res Commun. 186:1992;1626-1630.
29. Valadon P., Dansette P.M., Girault J.-P., Amar C., Mansuy D. Thiophene sulfoxides as reactive metabolites Formation upon microsomal oxidation of a 3-aroylthiophene and fate in the presence of nucleophiles in vitro and in vivo . Chem Res Toxicol. 9:1996;1403-1413.
30. Lopez-Garcia M.P., Dansette P.M., Mansuy D. Thiophene derivatives as new mechanism-based inhibitors of P450 Inactivation of yeast-expressed human liver P450 2C9 . Biochemistry. 33:1994;166-175.
31. Nieves-Neira W., Rivera M.I., Hursey M., Sausville E.A., Pommier Y. DNA damage induced by the thiophene NSC 652287 in renal cell lines of the National Cancer Institute (NCI) Anticancer Drug Screen. Proc Am Assoc Cancer Res. 39:1998;223.